Sotorasib Tablets Market Report 2025

The sotorasib tablets market size has grown rapidly in recent years. It will grow from $1.71 billion in 2024 to $1.92 billion in 2025 at a compound annual growth rate (CAGR) of 12.5%. Growth in the historic period was driven by the increasing prevalence of non-small cell lung cancer, rising awareness of targeted cancer therapies, growing adoption of precision medicine, expansion of oncology treatment centers, and increasing government support for cancer drugs.

The sotorasib tablets market size is expected to see rapid growth in the next few years. It will grow to $3.04 billion in 2029 at a compound annual growth rate (CAGR) of 12.1%. Growth in the forecast period is expected to be supported by rising investment in KRAS inhibitor research, expansion of sotorasib manufacturing capacity, increasing collaborations between biotech and pharmaceutical companies, growing demand for personalized cancer treatment, and wider adoption of oral targeted therapies. Key trends anticipated for the forecast period include advancements in targeted therapy development, improvements in KRAS mutation detection methods, increased R&D investment in oncology drugs, innovation in oral cancer formulations, and progress in sustainable drug manufacturing practices.

The increasing prevalence of cancer is expected to drive the growth of the sotorasib tablets market in the coming years. Cancer consists of a group of diseases characterized by the uncontrolled growth of abnormal cells that invade surrounding tissues and may spread to other parts of the body. This rising prevalence is largely attributed to an aging population, as older individuals are at significantly higher risk for developing various forms of cancer, with the majority of cases occurring in people over the age of 65. Sotorasib tablets function by selectively and irreversibly targeting the KRAS G12C mutation, effectively locking the mutated protein in an inactive state to prevent the uncontrolled cell growth seen in advanced solid tumors, particularly in cases of non-small cell lung cancer. For example, in February 2024, the World Health Organization, an international organization based in Switzerland focused on public health, reported that over 35 million new cancer cases are projected by 2050, representing a 77 percent increase from the estimated 20 million cases in 2022. Therefore, the growing cancer burden is contributing to the expansion of the sotorasib tablets market.

Key companies operating in the sotorasib tablets market are advancing combination therapies to improve outcomes and overcome treatment resistance. Combination therapies involve the use of two or more drugs that work together to attack cancer through multiple mechanisms. This approach enhances treatment efficacy, delays or overcomes resistance, reduces the chances of recurrence, and improves patient quality of life. For instance, in January 2025, Amgen Inc., a biotechnology company based in the United States, received approval from the United States Food and Drug Administration for the use of sotorasib in combination with panitumumab for adult patients with metastatic colorectal cancer carrying the KRAS G12C mutation who had previously undergone standard chemotherapy. This approval followed the results of the Phase 3 CodeBreaK 300 study, which showed that the combination more than doubled progression-free survival compared to the standard-of-care treatment chosen by investigators. Sotorasib is the first oral inhibitor of the KRAS G12C mutation, functioning by selectively binding to the mutant KRAS protein in its inactive form to halt tumor growth and block cancer-related signaling pathways.

In October 2022, BridgeBio Pharma, a biopharmaceutical company based in the United States with a focus on genetic diseases and cancer, entered into a partnership with Amgen to assess the combination of BBP-398 and Lumakras in patients with non-small cell lung cancer harboring the KRAS G12C mutation. The goal of this partnership is to explore a potentially more effective therapeutic approach for these patients, addressing the significant unmet needs associated with this specific mutation. Amgen is a biopharmaceutical company in the United States that develops therapies for serious illnesses, including sotorasib, a treatment for cancers involving KRAS G12C mutations.

Major players in the sotorasib tablets market are Amgen Inc., Ziska Pharmaceuticals Limited, Everest Pharmaceuticals Inc., Lucius Pharmaceutical Co. Ltd.

North America was the largest region in the sotorasib tablets market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in sotorasib tablets report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the sotorasib tablets market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Sotorasib tablets are a prescription medicine developed for treating certain cases of non-small cell lung cancer in patients whose tumors carry the KRAS G12C gene mutation. The drug binds to the abnormal KRAS protein, preventing it from transmitting signals that drive uncontrolled cancer cell growth and survival. This targeted inhibition can reduce tumor activity, slow disease progression, and improve treatment outcomes in patients with limited options from standard therapies.

The primary dosage forms of sotorasib tablets include 40 mg, 120 mg, 240 mg, and other strengths. The 40 mg tablets provide a lower-strength option for precise dose adjustments to enhance safety and tolerability. Sotorasib is used across patient populations including adolescents, adults, and seniors. Distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and others. Key applications include non-small cell lung cancer, colorectal cancer, and additional indications, with end-users comprising hospitals, oncology centers, clinics, and other healthcare providers.

The sotorasib tablets market research report is one of a series of new reports that provides sotorasib tablets market statistics, including sotorasib tablets industry global market size, regional shares, competitors with the sotorasib tablets market share, sotorasib tablets market segments, market trends, and opportunities, and any further data you may need to thrive in the sotorasib tablets industry. This sotorasib tablets market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The sotorasib tablets market consists of sales of lumakras, lumykras, and diagnostic companion kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.